Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation has announced promising results from a Phase 2a clinical trial showing that their treatment with imdusiran and VTP-300 significantly lowered HBsAg levels in chronic hepatitis B patients, which may potentially allow them to stop standard NA therapy. The treatment was well-tolerated with no serious adverse events, and a significant number of patients in the treatment arm met criteria to discontinue NA therapy. These findings were presented at the EASL Congress and further data is expected later in the year.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
